Search research articles
Contact Us
Filters
Showing results (61-70 of 83) with videos related to
Page
of 9
Sort By:
Liver International : Official Journal of the International Association for the Study of the Liver
|
January 31, 2024
Hepatitis C virus reinfection incidence among gay and bisexual men with HIV in Australia from 2016 to 2020
Brendan L Harney, Rachel Sacks-Davis, Daniela K van Santen, et al.
Health Science Reports
|
August 24, 2022
Patterns and correlates of hepatitis C virus phylogenetic clustering among people living with HIV in Australia in the direct-acting antiviral era: A molecular epidemiology study among participants in the CEASE cohort
Sofia R Bartlett, Andrey Verich, Joanne Carson, et al.
Open Forum Infectious Diseases
|
April 1, 2024
Risk of Primary Incident Hepatitis C Infection Following Bacterial Sexually Transmissible Infections Among Gay and Bisexual Men in Australia From 2016 to 2020
Brendan L Harney, Rachel Sacks-Davis, Paul Agius, et al.
Lancet (London, England)
|
February 7, 2026
Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on oral antiretroviral therapy: 48-week results of a phase 3, multicentre, randomised, open-label, non-inferiority trial
Chloe Orkin, Rosie Mngqibisa, Juan Diego Velez, et al.
Plos One
|
November 1, 2023
Clinical and laboratory features of COVID-19 illness and outcomes in immunocompromised individuals during the first pandemic wave in Sydney, Australia
Nila J Dharan, Sarah C Sasson, Golo Ahlenstiel, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
December 3, 2015
Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment: 48-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study
Anton Pozniak, Jose R Arribas, Joseph Gathe, et al.
The Journal of Infectious Diseases
|
July 20, 2005
Impact of therapeutic immunization on HIV-1 viremia after discontinuation of antiretroviral therapy initiated during acute infection
Sabine Kinloch-de Loes, Bruno Hoen, Don E Smith, et al.
The Lancet. HIV
|
October 2, 2015
Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial
Jürgen K Rockstroh, Mark Nelson, Christine Katlama, et al.
The Lancet Regional Health. Western Pacific
|
September 12, 2024
Syphilis testing, incidence, and reinfection among gay and bisexual men in Australia over a decade spanning HIV PrEP implementation: an analysis of surveillance data from 2012 to 2022
Michael W Traeger, Rebecca Guy, Caroline Taunton, et al.
Nature Medicine
|
June 8, 2021
HIV is associated with an increased risk of age-related clonal hematopoiesis among older adults
Nila J Dharan, Paul Yeh, Mark Bloch, et al.
Page
of 9
Search research articles
Search
Showing results (61-70 of 83) with videos related to
Sort By:
Page
of 9
Liver International : Official Journal of the International Association for the Study of the Liver
|
January 31, 2024
Hepatitis C virus reinfection incidence among gay and bisexual men with HIV in Australia from 2016 to 2020
Brendan L Harney, Rachel Sacks-Davis, Daniela K van Santen, et al.
Health Science Reports
|
August 24, 2022
Patterns and correlates of hepatitis C virus phylogenetic clustering among people living with HIV in Australia in the direct-acting antiviral era: A molecular epidemiology study among participants in the CEASE cohort
Sofia R Bartlett, Andrey Verich, Joanne Carson, et al.
Open Forum Infectious Diseases
|
April 1, 2024
Risk of Primary Incident Hepatitis C Infection Following Bacterial Sexually Transmissible Infections Among Gay and Bisexual Men in Australia From 2016 to 2020
Brendan L Harney, Rachel Sacks-Davis, Paul Agius, et al.
Lancet (London, England)
|
February 7, 2026
Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on oral antiretroviral therapy: 48-week results of a phase 3, multicentre, randomised, open-label, non-inferiority trial
Chloe Orkin, Rosie Mngqibisa, Juan Diego Velez, et al.
Plos One
|
November 1, 2023
Clinical and laboratory features of COVID-19 illness and outcomes in immunocompromised individuals during the first pandemic wave in Sydney, Australia
Nila J Dharan, Sarah C Sasson, Golo Ahlenstiel, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
December 3, 2015
Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment: 48-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study
Anton Pozniak, Jose R Arribas, Joseph Gathe, et al.
The Journal of Infectious Diseases
|
July 20, 2005
Impact of therapeutic immunization on HIV-1 viremia after discontinuation of antiretroviral therapy initiated during acute infection
Sabine Kinloch-de Loes, Bruno Hoen, Don E Smith, et al.
The Lancet. HIV
|
October 2, 2015
Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial
Jürgen K Rockstroh, Mark Nelson, Christine Katlama, et al.
The Lancet Regional Health. Western Pacific
|
September 12, 2024
Syphilis testing, incidence, and reinfection among gay and bisexual men in Australia over a decade spanning HIV PrEP implementation: an analysis of surveillance data from 2012 to 2022
Michael W Traeger, Rebecca Guy, Caroline Taunton, et al.
Nature Medicine
|
June 8, 2021
HIV is associated with an increased risk of age-related clonal hematopoiesis among older adults
Nila J Dharan, Paul Yeh, Mark Bloch, et al.
Page
of 9